Literature DB >> 2406811

Vascular disease in scleroderma. Endothelial T lymphocyte-fibroblast interactions.

M B Kahaleh1.   

Abstract

The accumulated body of evidence suggests a role for a cell-mediated immune mechanism in the pathogenesis of scleroderma vascular disease. The most likely target for immune injury is either the endothelial cell itself or components of its basal lamina, which include type IV collagen and laminin. Whatever the specific target, the net effect is persistently altered endothelial cell dysfunction. However, the molecular basis for the development of endothelial cell injury is not known. Direct investigations of perivascular infiltrating cells have not been possible yet; published studies have focused on the in vitro effects of peripheral blood mononuclear cells and selected cytokines on endothelial cell behavior and function. Understanding the multiple cellular effects of various cytokines on endothelial cells may further the knowledge of the vascular disease. Systematic study of interactions between endothelial cells and cells of the immune system may provide the molecular basis for vascular injury and open yet unidentified avenues for therapy. Furthermore, monitoring parameters of endothelial cell injury may help to define the disease in an earlier and more meaningful fashion. Circulating levels of EC products such as von Willebrand factor, plasminogen activator, and prostacyclin/thromboxane metabolites may permit a precise definition of disease activity and assist the clinician in monitoring responses to therapy.

Entities:  

Mesh:

Year:  1990        PMID: 2406811

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  9 in total

1.  Serum laminin and basic fibroblast growth factor concentrations in patients with complicated Plasmodium falciparum malaria.

Authors:  H Burgmann; S Looareesuwan; C Viravan; S Vanijanonta; K Zedwitz-Liebenstein; H Vorbach; W Graninger
Journal:  J Clin Immunol       Date:  1996-09       Impact factor: 8.317

2.  Homocysteine and laminin are not prognostic markers in patients with septic inflammatory response syndrome.

Authors:  B Stoiser; F Thalhammer; I El-Menyawi; A Wilfing; F Daxböck; G J Locker; H Burgmann
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

Review 3.  A brief overview of the pathogenesis of scleroderma (systemic sclerosis).

Authors:  E C LeRoy
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

4.  Lipoprotein profile in limited systemic sclerosis.

Authors:  Eduardo F Borba; Claudia T L Borges; Eloísa Bonfá
Journal:  Rheumatol Int       Date:  2005-02-08       Impact factor: 2.631

Review 5.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

6.  A recombinant topoisomerase I ELISA: screening for IgG, IgM and IgA anti-topo I autoantibodies in human sera.

Authors:  R Verheijen; B A de Jong; W J van Venrooij
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

7.  Computer based quantitative analysis of capillary abnormalities in systemic sclerosis and its relation to plasma concentration of von Willebrand factor.

Authors:  A Scheja; A Akesson; I Niewierowicz; L Wallin; M Wildt; F A Wollheim
Journal:  Ann Rheum Dis       Date:  1996-01       Impact factor: 19.103

Review 8.  New perspectives on basic mechanisms in lung disease. 1. Lung injury, inflammatory mediators, and fibroblast activation in fibrosing alveolitis.

Authors:  M N Sheppard; N K Harrison
Journal:  Thorax       Date:  1992-12       Impact factor: 9.139

Review 9.  The aetiopathogenesis of systemic sclerosis: thick skin--thin hypotheses. The Parkes Weber Lecture 1994.

Authors:  C M Black
Journal:  J R Coll Physicians Lond       Date:  1995 Mar-Apr
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.